Welcome to our dedicated page for AMGEN SEC filings (Ticker: AMGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amgen Inc. SEC filings document the regulatory record for a Nasdaq-listed biotechnology company with common stock and registered debt securities. Its 8-K reports cover quarterly and annual earnings releases, Regulation G reconciliations for non-GAAP measures, free cash flow disclosures, material definitive agreements, executive leadership changes and capital markets transactions.
The company's proxy materials describe annual meeting matters, board governance, executive compensation and stockholder voting procedures. Other filings address senior note offerings under registration statements and indentures, Nasdaq listing and registration matters for debt securities, and formal exhibits that define the terms of financing, governance and corporate disclosure events.
Amgen Inc. senior vice president of business development Rachna Khosla reported a set of option-related and open-market transactions. On 2026-08-13 she exercised 1,252 options at $162.60 per share to acquire 1,252 common shares, then sold those 1,252 shares at an average price of $416.4256, including shares sold to cover the option exercise price and required withholding taxes. She also sold 2,000 common shares on 2026-08-11 at an average price of $412.567 per share.
Rachna Khosla, affiliated with Amgen Inc., has filed a Form 144 indicating an intention to sell up to 516,775 shares of Amgen common stock through Fidelity Brokerage Services LLC, with an approximate sale date of 08/13/2026 on NASDAQ. The securities are reported as acquired on 08/11/2026 via a stock option exercise from the issuer as compensation. Over the past three months, Khosla has already sold 2,000 shares of Amgen common stock for gross proceeds of $825,084.05.
Busch Matthew C. reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. reported that officer Matthew C. Busch, VP, Finance & CAO, received an equity compensation award of 730 shares of Common Stock in the form of Restricted Stock Units (RSUs) on 2026-08-07. The RSUs were granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vest in four equal annual installments of 25%, beginning on 8/7/2027. Vested RSUs will be settled in shares of Amgen common stock on a one-to-one basis. Following this award, Busch holds 5,080 shares directly, which include 45 Dividend Equivalents (DEs) credited to his unvested RSUs.
A holder of Amgen (AMGN) common stock filed a notice of intent to sell up to 2,000 shares through Fidelity Brokerage Services LLC on NASDAQ, with an indicated aggregate market value of about $828,420. The shares were originally received as stock awards from the issuer on multiple compensation grant dates in 2022 and 2023.
Amgen Inc. director Omar Ishrak reported an acquisition of 85.1685 shares of Amgen common stock on 2026-08-07 as a grant or award, at a stated price of $0.0000 per share. Following this award, he holds 7,485.9046 shares directly. A related footnote states that these holdings include 460 Dividend Equivalents (DEs) credited to unvested Restricted Stock Units under Amgen’s Second Amended and Restated 2009 Equity Incentive Plan, which are paid out in common shares on a one-to-one basis according to the RSU vesting schedule, with any remaining fractional share settled in cash.
AMGEN INC director Charles M. Holley reported a compensation-related acquisition of 103.4189 shares of common stock on 2026-08-07, recorded at a price of $0.0000 per share. Following this grant, he holds 12,990.4520 shares directly, which include 1,652 Dividend Equivalents credited to unvested Restricted Stock Units under Amgen’s equity incentive plan. He also reports 1,260.0000 shares held indirectly through the Holley Family Trust.
Drake Michael V reported acquisition or exercise transactions in this Form 4 filing.
AMGEN INC director Michael V. Drake reported an automatic grant/award of 63.8764 shares of common stock on 2026-08-07, at a stated price of $0.0000 per share as compensation. Following this award, his directly held position is 5,876.1633 shares, including 377 Dividend Equivalents linked to unvested Restricted Stock Units that pay out in common stock on a one-to-one basis as they vest.
Amgen Inc. executive Derek Miller, SVP of Human Resources, exercised stock options for a total of 3,890 shares of common stock on August 6, 2026, at strike prices of $162.60 and $177.46 per share. He then sold 3,890 common shares at a weighted-average price of $402.5444 per share in open market or private transactions. Footnotes state these sales include shares used to cover the option exercise price and required withholding taxes, and separately describe 117 dividend equivalents credited to unvested restricted stock units under Amgen's equity incentive plan.
Amgen Inc. executive Nancy A. Grygiel, SVP & CCO, exercised nonqualified stock options for 1,970 and 1,000 shares of common stock on August 6, 2026, at exercise prices of $177.46 and $177.31 per share, respectively. She then sold 2,970 shares of common stock at $402.1601 per share in reported market transactions. According to the disclosure, the sales included shares used to cover the option exercise price and required withholding taxes related to expiring options. Following these transactions, 106.9449 shares are held indirectly through the company’s 401(k) Plan, and a portion of her reported holdings includes 68 Dividend Equivalents credited to unvested Restricted Stock Units.